A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy

INTRODUCTION: The clinical features of patients with metastatic epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma receiving first-line therapy based on erlotinib combined with bevacizumab are unclear. Here, we sought to analyze the clinical features of this patient group. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chin-Chou, Chiu, Li-Chung, Tung, Pi-Hung, Kuo, Scott Chih-Hsi, Chu, Chia-Hsun, Huang, Allen Chung-Cheng, Wang, Chih-Liang, Chen, Chih-Hung, Yang, Cheng-Ta, Hsu, Ping-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593121/
https://www.ncbi.nlm.nih.gov/pubmed/33990928
http://dx.doi.org/10.1007/s40487-021-00152-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593121/
https://www.ncbi.nlm.nih.gov/pubmed/33990928
http://dx.doi.org/10.1007/s40487-021-00152-6

Ejemplares similares